Cipla Ltd.

1,313

-2 (-0.2%)growUp

As on January 27, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap1,06,187 Cr
P/E Ratio20.11
Dividend Yield0.61 %
Trendline Performance

Unlock_ipo_icon.webpUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open1,300
High1,323.5
NSE SymbolCIPLA
Close1,313
Low1,281.7
BSE Symbol500087
Previous Years High/Low
1 Year High1,673
3 Year High1,702.05
5 Year High1,702.05
1 Year Low1,281.7
3 Year Low852
5 Year Low738.1

Technicals


IndicatorsValueSignal
5-DMA1,349.28Bearish
10-DMA1,388.42Bearish
20-DMA1,441.96Bearish
50-DMA1,484.32Bearish
100-DMA1,515.64Bearish
200-DMA1,512.03Bearish

Historical Performance


1 Year
-6%
3 Years
25.4%
5 Years
55.8%
10 Years
126.2%

Shareholding Pattern


Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Net Sales2,75,4762,57,7412,27,5312,17,6331,91,596
Total Expenditure2,04,1971,94,8301,77,6281,72,5141,49,109
Other Income8,6197,4665,1213,2172,698
Operating Profit79,89870,37655,02448,33745,184
Interest6208991,0951,0631,607
Depreciation11,06910,51011,72110,51910,677
Profit Before Tax68,20857,01940,38434,93332,901
Consolidated Net Profit52,72541,21528,01925,16824,049
Adjusted EPS6551353130
Compounded Sales Growth
10 Years:19.4
5 Years:10
3 Years:4.8
TTM:1.3
Compounded Profit Growth
10 Years:34.9
5 Years:27.8
3 Years:15.9
TTM:5
Stock Price CAGR
10 Years:8.6
5 Years:9.3
3 Years:7.8
TTM:-7.6
Return on Equity
10 Years:16.9
5 Years:29.8
3 Years:34.7
last year:65.3

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Share Capital1,6151,6151,6141,6141,613
Total Reserves3,09,1782,64,5842,31,8452,06,3631,81,232
Long-Term Borrowings---------------
Total Non-Current Liabilities-3108191,8356,21716,601
Other Current Liabilities7,7308,91010,0767,69810,932
Short Term Borrowings8012,4701,8793,9333,347
Total Liabilities3,67,4223,21,3002,90,0672,66,5232,48,372
Capital Work in Progress12,1288,6436,8923,8295,708
Long Term Loans & Advances10,3848,4448,4957,3646,456
Currents Investments72,93248,07030,89921,95022,864
Short Term Loans and Advances34,81431,34225,63215,07110,310
Total Current Assets2,32,4901,93,9241,68,0511,47,1081,31,810
Total Assets3,67,4223,21,3002,90,0672,66,5232,48,372
Adjusted Book Value385330289258227
0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a moderate PE of 20.11, suggesting fair valuation relative to earnings.
  • Over the last three years, the stock delivered a moderate 3-year price CAGR of 8.3%, reflecting average market performance.
  • The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
  • In the last financial year, the company reported an EBITDA of ₹79898 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹275476 million, indicating a large and established business.

Investment Calculator


Investment Amount:

Investment Amount: ₹ 1000000
Current Value: ₹ 924257.4
No. of Shares: 704 (Approx)
Performance:-7.6%
P/L: ₹-75742.6
NIFTY Performance: 9.7%
1 day Top Gainers
SymbolChange%
HOMEFIRST1251.7(13%)
KARURVYSYA292.55(10%)
JSL810.05(9%)
SONACOMS487.8(7%)
GRSE2387.6(7%)
1 Day Top Losers
SymbolChange%
SBFC89.97(-12%)
SYNGENE489.7(-10%)
JSWENERGY440.05(-8%)
SUNTV529.9(-6%)
GODREJCP1173.9(-5%)
GRAVITA1466.3(-5%)
CREDITACC1320.6(-5%)
NUVAMA1265.2(-5%)

Top Performing Stocks from the same sector


Mangalam Drugs And Organics Ltd.

77.5%

42.21

1 Month Performance

NGL Fine-Chem Ltd.

18.4%

1566.2

1 Month Performance

Ind-Swift Laboratories Ltd.

16.9%

107.02

1 Month Performance

Torrent Pharmaceuticals Ltd.

4.7%

3997.4

1 Month Performance

Acutaas Chemicals Ltd.

4.5%

1728

1 Month Performance

Emcure Pharmaceuticals Ltd.

4%

1484.6

1 Month Performance

Alkem Laboratories Ltd.

4%

5754

1 Month Performance

JB Chemicals & Pharmaceuticals Ltd.

3.2%

1877.5

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month